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Besides their innate ability to rapidly produce effector cytokines and kill virus-infected or transformed cells, natural killer
(NK) cells display a strong capability to adapt to environmental modifications and to differentiate into long-lived,
hyperfunctional populations, dubbed memory or memory-like NK cells. Despite significant progress in the field of NK
cell-based immunotherapies, some factors including their short life span and the occurrence of a tumor-dependent functional
exhaustion have limited their clinical efficacy so that strategies aimed at overcoming these limitations represent one of the main
current challenges in the field. In this scenario, the exploitation of NK cell memory may have a considerable potential. This
article summarizes recent evidence in the literature on the peculiar features that render memory NK cells an attractive tool for
antitumor immunotherapy, including their long-term survival and in vivo persistence, the resistance to tumor-dependent
immunosuppressive microenvironment, the amplified functional responses to IgG-opsonized tumor cells, and in vitro expansion
capability. Along with highlighting these issues, we speculate that memory NK cell-based adoptive immunotherapy settings
would greatly take advantage from the combination with tumor-targeting therapeutic antibodies (mAbs), as a strategy to fully
unleash their clinical efficacy.
1. Introduction
NK cells represent a pivotal player of innate antitumor
immune responses. They can eradicate neoplastic cells by a
targeted release of cytotoxic granules containing perforin
and granzymes and/or death receptor-mediated killing [1].
Moreover, NK cells can signal to other immune cells by pro-
ducing cytokines and chemokines, such as IFN-γ, TNFα,
IL-6, GM-CSF, and CCL5 in response to target cells or cyto-
kine stimulation [1, 2]. In particular, NK-derived IFN-γ
stands as a well-recognized key immunoregulatory factor in
the shaping of antitumor adaptive immune responses, by
modulating dendritic cell (DC) and T cell responses [3–5].
Further, NK cell-mediated antibody-dependent cellular cyto-
toxicity (ADCC) is amain immune-dependentmechanism by
which tumor-targeting therapeutic mAbs mediate tumor cell
killing [6–8].
NK cell functional response to tumor cells encounter is
triggered by a variety of activating receptors, some of which
(e.g., NKG2D and DNAM-1) recognize stress-induced
ligands expressed on malignantly transformed cells; addi-
tionally, NK cells are potently activated by CD16 or FcγRIIIa
(low-affinity Fc receptor for IgG)-dependent recognition of
IgG-opsonized targets. In contrast, individual NK cells
express, in different combinations, several inhibitory recep-
tors (e.g., CD94/NKG2A and killer immunoglobulin-like
receptors (KIR)) that recognize MHC class I molecules.
In addition to modulate functional responsiveness, NK
cell inhibitory receptors are critical for promoting their
education [9].
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The perspective of NK cells as exquisitely innate effectors
is challenged by the recent appreciation that NK cells can
adapt their functional program in response to environmental
factors, through the generation of long-lasting specialized
NK cell populations with enhanced effector functions, named
adaptive or memory NK cells [10–12].
The first demonstration of antigen-specific recall
responses by NK cells was in the setting of hapten-induced
contact hypersensitivity, whereCXCR6+ liver-derivedmurine
NK cells could mediate antigen-specific contact hypersensi-
tivity independently from B and T cells [13, 14].
Doubtless, memory NK cell populations have been
mostly extensively characterized in the setting of cytomegalo-
virus (CMV) infection. Murine CMV (MCMV) infection
induces immunological memory independent of T and B
cells [15, 16]. Protection in these models is mediated by
Ly49H+ NK cells, which upon recognition of m157 viral anti-
gen (Ly49H ligand) proliferate and persist in lymphoid and
nonlymphoid organs. Upon reinfection, these memory NK
cells undergo secondary expansion, rapidly degranulate,
and release cytokines, leading to a protective immune
response, and also provide protection to newborn mice chal-
lenged with MCMV, upon adoptive transfer [16].
Accordingly, human CMV (HCMV) deeply impacts on
NK cell compartment; in such context, memory NK cells
have been initially identified in healthy HCMV-seropositive
individuals, mainly on the basis of high expression levels of
CD94/NKG2C activating receptor and CD57 terminal dif-
ferentiation marker [17–21]. Such NKG2C+ memory NK
cells can constitute up to 70% of the total NK cell population
and can persist at high frequency for years [22–25].
Similar to Ly49H in mice, NKG2C is a member of the
C-type lectin superfamily and associates to the adaptor pro-
tein DAP12 [26]. NKG2C forms heterodimers with CD94
and binds to the nonclassical MHC class I molecule HLA-E
bound to HLA-E-stabilizing peptides [27].
HCMV-associated NK cells exhibit a distinct surface
receptor expression pattern, consisting of a reduced
expression of NKG2A (the inhibitory receptor counterpart
of NKG2C), NKp30, NKp46, and CD16, as well as an
increased expression of ILT2 (LIR-1a) [11, 19]. Further,
it has been reported that ex vivo memory NK cells display
an oligoclonal KIR pattern, with a bias for self-specific
members both in healthy donors and chronic hepatitis
patients [18, 24].
These features, along with additional phenotypic hall-
marks, including the preferential expression of the activating
receptor CD2, together with the reduced expression of the
inhibitory receptor Siglec-7 [28], collectively aid in the iden-
tification of this unique and discrete NK cell population.
A link between HCMV andmemory NK cell expansion is
supported by the finding of an increase in CD94/NKG2C+
NK cells following the HCMV reactivation or infection
in patients receiving hematopoietic stem cell transplant
[22, 23, 29–31] and strengthened by the recent identification
of HCMV-encoded antigen UL40, as the HLA-E ligand that
drives the in vitro expansion and differentiation of memory
NKG2C+ NK cells [32]; however, a potential role of other
receptors besides NKG2C in the recognition and response
to HCMV infection and in the skewing of an identical cellular
program has been proposed [33].
Seminal independent studies have identified an
immune-receptor tyrosine-based activation motif (ITAM)-
bearing FcεRIγ adaptor protein-deficient NK cell subset
in HCMV-seropositive individuals, endowed with a spe-
cific epigenetic signature, mostly overlapping with the
CD94/NKG2C+ population [19–21, 34, 35]. FcεRIγ chain
deficiency became an important feature of memory NK cell
population, together with the specific downregulation of
PLZF and IKZF2 transcription factors, as well as the variable
loss of the intracellular signaling molecules DAB2, SYK, and
EAT-2.
Memory NK cells also display a distinctive genome-wide
methylation profile that confers an overall epigenetic profile
very similar to that of memory CD8+ T cells, thus providing
a molecular basis for the adaptive features of these cells. In
particular, the promoter regions of FcεRIγ, EAT-2, SYK,
and PLZF genes are highly methylated in memory NK cells,
compared to conventional NK cells (cNK). Likewise, the pro-
moter regions of IL-12 and IL-18 receptor subunit genes,
which are regulated by PLZF, are also highly methylated,
accounting for a reduced ability to respond to bystander
activation by these cytokines [12, 21].
Another major epigenetic hallmark of memory NKG2C+
NK cells is represented by a significant demethylation of the
conserved noncoding sequence (CNS) 1 in the IFNG locus,
which remains stable in progeny, similar to what occurs
in memory Th1 cells [25]. This molecular signature pro-
vides a mechanism to explain the potent IFN-γ production
in response to the stimulation through a selective recogni-
tion repertoire. Indeed, the engagement of NKG2C by
HLA-E-expressing target cells potently activates memory
NK cells and leads to polyfunctional responses character-
ized by degranulation as well as TNFα and IFN-γ produc-
tion [18]. Further, memory NK cells can be efficiently
stimulated by the cross-linking of CD16 through the rec-
ognition of Ab-coated virus-infected cells [19, 21, 33, 34].
Long-lived memory-like NK cells can also be generated
in noninfectious or antigen-independent settings. Specifi-
cally, in vitro stimulation of mouse splenic NK cells with
IL-12 and IL-18, prior to transfer into a naive host, generated
a pool of cells with enhanced IFN-γ production in response
to cytokines, activating receptor ligands or tumor targets
[36, 37], without any enhanced cytotoxicity. Similar to
murine memory-like NK cells, when human NK cells are pre-
activated with IL-12, IL-15, and IL-18 and subsequently
rested for several days, they display an increased IFN-γ pro-
duction upon restimulation with cytokines or target cells
compared with control population and such enhanced activ-
ity is maintained following an extensive cell division [38, 39].
2. In Vivo Evidence of Memory NK Cell
Antitumor Activity
Preclinical and clinical observations suggest that memory
NK cell activities could be advantageous in tumor settings
and may contribute to relapse protection, in the context of
hematopoietic malignancies.
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Several studies reported a longer relapse-free survival
after allogeneic stem cell transplantation in acute myeloid
leukemia (AML) or chronic myeloid leukemia (CML)
patients experiencing HCMV reactivation [40–43]. More-
over, the expansion of NKG2C+CD57+ memory NK cells in
leukemic patients that reactivated CMV following
allo-hematopoietic stem cell transplant (HSCT) is associated
with a significantly reduced rate of relapse [44], suggesting
that the recognition of HLA-E+ leukemic blasts by memory
NKG2C+ NK cells expanded in response to HCMV infection
may have beneficial effect through the eradication of minimal
residual disease.
Furthermore, consistent with the finding that murine
cytokine-preactivated memory-like NK cells maintain
enhanced antitumor activity after adoptive transfer [38], a
single injection of human memory-like NK cells significantly
reduced the leukemia burden and improved the overall sur-
vival compared with that of control NK cells, in a xenograft
model of leukemia [45]. Similarly, an independent study
also found effective control of melanoma growth by
cytokine-preactivated human NK cells in a melanoma
xenograft model in NOD scid gamma (NGS) mice. The
enhanced antitumor effects mediated by memory-like NK
cells might result from their augmented cytotoxicity, high
IFN-γ production capacity, and persistence in large numbers
in the host [46].
More importantly, a phase I clinical trial harnessing
cytokine-induced memory-like NK cells was recently per-
formed in patients with relapsed or refractory AML [45],
which consisted in the adoptive transfer of donor-derived
NK cells preactivated with IL-12, IL-15, and IL-18, following
fludarabine/cyclophosphamide-mediated lymphodepletion.
Tracking donor memory-like NK cells in recipients revealed
that they underwent in vivo expansion. As expected, donor
memory-like NK cells displayed higher frequencies of IFN-γ+
cells with respect to recipient NK cells when challenged
ex vivo with K562 leukemia cells. Notably, five out of nine
evaluable patients showed a clinical response, including four
complete remissions, which compares favorably with previ-
ous studies utilizing purified NK cells without cytokine
preactivation [47].
3. Unique Features of Memory NK Cells
Exploitable in Cancer Immunotherapy
3.1. Long-Term Survival and In Vivo Persistence. A crucial
aspect of memory or memory-like NK cells is a longer life
span, with respect to conventional populations, along with
the capability to mediate persistent responses.
While NK cells are considered short-lived effectors of
innate immunity, with an estimated half-life of 14 days
[48, 49], HCMV-induced CD94/NKG2C+ NK cells exhibit
a persistence of several months in the absence of detect-
able viremia and were stably maintained at elevated fre-
quency for years, in some healthy individuals [22, 23, 30].
Moreover, after the umbilical cord blood transplantation in
patients with hematopoietic malignancies, CMV reactivation
leads to a long-lasting increase of NKG2C+ NK cells [29, 31].
Recent studies, involving patients with either paroxysmal
nocturnal hemoglobinuria or GATA2 deficiency, demon-
strate that memory NK cells selectively persist in these
patients in spite of a reduction of conventional NK cell popu-
lations, supporting an independent survival and self-renewal
pathway for the homeostatic maintenance of CD56+ NK cells
with an adaptive phenotype [50, 51].
Mechanistic studies demonstrated that human memory
NK cells express higher levels of antiapoptotic Bcl-2 that
marked an epigenetically unique population persisting for
at least 35 months [21, 34]. The authors speculate that,
analogously to long-lived and self-renewing memory T
cells, the reduced expression of PLZF could support memory
NK cell longevity.
More recently, an isoform of AT-rich interaction domain
5 (ARID5B) transcription factor has been found selectively
upregulated in memory NK cells and involved in promoting
mitochondrial membrane potential, oxidative metabolism,
survival, and IFN-γ production [52]. Collectively, such evi-
dence provides molecular basis for memory NK cell longevity
(Figure 1).
The MCMV infection model gave important insights on
memory NK cell longevity. The analysis of the proliferation
kinetics and persistence of MCMV-driven Ly49H+ NK cells
showed that following a contraction phase, a long-lived and
self-renewing memory cell pool persists for several months
after infection in a variety of peripheral tissues, where it dis-
plays an enhanced response to secondary challenge [16]. The
downregulation of the prosurvival molecule Bcl-2 and
Bim-mediated proapoptotic signaling during the contraction
phase regulate the size of the memory cell pool [53, 54].
Further, the survival of memory NK cells during the con-
traction phase after MCMV infection requires mitophagy
of dysfunctional mitochondria, through an Atg3-dependent
mechanism [55].
3.2. Resistance to Tumor-Dependent Immunosuppressive
Microenvironment. Although NK cells are expected to
target malignant cells and to play an important role in
the immune surveillance against tumors, it is now appre-
ciated that the suppressive components in the tumor
microenvironment dampen the NK cell efficacy [56, 57].
Several studies have revealed a central role for Treg in sup-
pressing tumor-infiltrating NK cells [58, 59]; in this context,
Treg-mediated suppression of ADCC has been shown to
correlate with a lower clinical efficacy of therapeutic
tumor-targeting mAbs [60]. Treg can act both by secreting
immunosuppressive cytokines (TGFβ, IL-10, and IL-35)
and by expressing inhibitory receptors (e.g., CTLA4 and
PD-1) on their surface. Recent data uncover a new mecha-
nism for Treg-mediated suppression of NK cells, based on
the production of IL-37 which promotes the downregulation
of the T cell immunoglobulin and mucin-domain
containing-3 (Tim-3), that may behave as a stimulatory
receptor in NK cells [61], and the upregulation of PD-1.
Compared with cNK cells, whose proliferation, IFN-γ pro-
duction, and cytotoxicity were efficiently inhibited by Treg,
memory NK cells were found to be inherently resistant to
Treg-mediated suppression, as they expressed low levels of
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IL-37 receptor, IL1R8, and PD-1, along with high levels of
Tim-3 [62].
Further, NK cells express an inhibitory receptor called
T cell immunoreceptor with immunoglobulin and immunor-
eceptor tyrosine-based inhibition motif domain (TIGIT),
which also marks exhausted CD8+ tumor-infiltrating lym-
phocytes (TIL) [63]. TIGIT along with CD96 (also known
as TACTILE) are coinhibitory receptors which by recogniz-
ing the same ligands of DNAM-1, namely, PVR (CD155)
and nectin-2 [64, 65], counterbalance DNAM-1 activation
at the NK-target synapse. Similar to T cells, in vitro blockade
of TIGIT enhances cytokine secretion and cytotoxicity in NK
cells [66–68] (Figure 1).
Recently, NK cell inhibition by myeloid-derived suppres-
sor cells (MDSC) was shown to rely on TIGIT-PVR axis and
was consequently abrogated upon TIGIT blockade. Also in
this case, memory NK cells were found to be resistant to
MDSC-mediated suppression in patients with cancer [68].
mAb-mediated interference with MHC class I-specific
inhibitory receptors of NK cells can represent a strategy to
potentiate their antitumor functions. In this regard, NKG2A
blockade by means of a specific mAb (IPH2201, monalizu-
mab) is currently being evaluated for a variety of tumor
types in combination, for instance, with tumor-targeting
mAbs [69]. The lack of NKG2A inhibitory receptor on
memory NK cells makes such cells inherently resistant to
HLA-E-expressing tumor-mediated inhibition and repre-
sents another advantage for the possible exploitation of
these cells.
3.3. Amplified Functional Responses to IgG-Opsonized
Targets. CD16 represents a prototype NK activating recep-
tor; its engagement by IgG-opsonized targets is sufficient to
trigger ADCC, as well as the production of proinflammatory
cytokines and chemokines, such as IFN-γ, TNFα, IL-6,
GM-CSF, and CCL5 [1, 2, 70, 71]. Human CD16 exhibits
two extracellular Ig domains, a short cytoplasmic tail and a
transmembrane domain that enables its association with
ITAM-containing CD3ζ and FcεRIγ chains [72], which guar-
antee Syk- and ZAP-70-dependent signal transduction [2].
Notably, CD16-triggered ADCC and phagocytosis, per-
formed by NK cells and macrophages, respectively, are
among the main immune-dependent mechanisms by which
tumor-targeting therapeutic mAbs mediate tumor cell
killing [6–8].
A key feature of memory NK cells is their capabil-
ity to mediate amplified Ab-dependent functional
responses in terms of degranulation and cytokine production
[19–21, 33, 34]. In particular, memory NK cells exhibit a
greatly enhanced ability to produce IFN-γ, as a consequence
of hypomethylated IFNG regulatory region [25], in response
to activation via CD16, thus providing a prompt and power-
ful response against Ab-opsonized target cells. Indeed,
despite the lower CD16 expression, they have been shown
to more efficiently mediate polyfunctional responses, e.g.,
degranulation and IFN-γ production, upon stimulation via
Ab-opsonized targets. The apparent conflict between higher
CD16-triggered functional responses and lower surface
receptor levels may be explained by the exclusive coupling
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Figure 1: NKG2C+ memory NK cell features exploitable in cancer immunotherapy. The dotted lines indicate reduced receptor expression.
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of CD16 to CD3ζ chain in memory NK cells that, thanks to
ITAM motif quantitative differences (3 ITAM in CD3ζ vs.
1 ITAM in FcεRIγ), may lead to more robust and efficient
biochemical signals [70] (Figure 1). Moreover, the residual
levels of CD3ζ chain may preserve the CD2/CD58 costimula-
tory interaction [73].
The enhanced response to CD16 stimulation has been
well documented in response to antiviral IgG-opsonized
infected cells and, of relevance here, to tumor-targeting ther-
apeuticmAb-opsonized tumor cells [19, 21, 33, 34, 74].More-
over, hyperresponsiveness to anti-CD20 mAb-opsonized
tumor cells was also observed in in vitro expanded memory
NK cells [74].
The capability of memory NK cells to activate in response
to tumor cells has not been satisfactorily demonstrated yet.
The reduction of NKp46 levels may explain the reduced
ability of fresh and in vitro cultured memory NK cells to
mediate effector functions in response to stimulation with
K562 target cells, being its recognition largely dependent
on this receptor [75]. However, NKG2C+ memory NK
cells from HCMV-reactivating patients efficiently produced
IFN-γ upon K562 stimulation [23, 44], indicating that the
upregulation of other activating receptors may compensate
for NKp46 defect. For example, CD2 ligand CD58, widely
expressed by tumor B cells, has been shown to costimulate
memory NK cell responses [33].
3.4. In Vitro Expansion Capability. In vitro expansion
of NKG2C+ memory NK cells can be achieved by
coculturing NK cells with CMV-infected fibroblasts or
HLA-E-transfected cell lines [24, 76]. In these conditions,
the interaction between CD94/NKG2C and its cellular ligand
HLA-E, in combination with inflammatory cytokines, such as
monocyte-derived IL-12, was critical for their expansion [77].
More recently, an HLA-E+ feeder cell-based protocol was
shown to induce the selective in vitro expansion of memory
NKcells that exhibited a profound skewing toward the expres-
sion of a single self-KIR, depending on the donor HLA-C
genotype. These cells showed a high NKG2C-dependent
cytotoxic potential against allogeneic pediatric acute lym-
phoblastic leukemia primary blasts [78], previously shown
to be refractory to killing by allogeneic NK cells or NK92
NK cell line [79]. These data envisage a potential exploita-
tion of memory NK cell alloreactivity in the context of novel
adoptive cell therapy strategies.
Different lines of evidence highlight that primary HCMV
infection drives the priming and proliferation of memory NK
cells in a NKG2C-dependent manner [10–12, 76, 77].
HCMV-driven memory NK cell pool can be maintained by
a variety of different viral super infections. In particular, an
expanded population of memory NK cells was detected in
EBV-, HBV-, HCV-, and HIV-seropositive individuals, only
when patients were also seropositive for HCMV [18, 80]. It
is therefore conceivable that Ab-mediated immune responses
may drive the proliferation and maintenance of an already
existing pool of memory NK cells, in some viral disease
settings. Indeed, the capability of CD16-initiated signals to
regulate NK cell proliferation and death, under selected
conditions, has been shown [81, 82].
Seminal in vitro studies offered a mechanistic explanation
for the role of virus-specific Abs in sustaining memory NK
cell expansion and established a pivotal role for CD16 bind-
ing to antiviral IgG-opsonized cells to induce the prolifera-
tion of this specific subset [20, 21].
In this context, our recent data [74] demonstrate the
unique capability of anti-CD20 therapeutic mAb-opsonized
targets to drive the selective in vitro expansion of memory
NK cells from HCMV-seropositive healthy donors. Indeed,
we developed an effective in vitro culture system, consisting
of a 9-day coculture of PBMCwith irradiated lymphoblastoid
Raji cells opsonized with anti-CD20 therapeutic mAbs, in
IL-2-containing medium (Figure 1). Importantly, in vitro
expanded memory NK cells, as their freshly isolated counter-
part, displayed amplified CD16-polyfunctional responses
upon stimulation with anti-CD20-opsonized tumor cells.
It is conceivable that CD16-dependent memory NK cell
proliferation also relies on multiple accessory signals, con-
veyed by cell-cell contacts and soluble mediators. In our
system, ligands expressed by Raji lymphoblastoid B cells
may provide accessory proliferative signals to memory
NK cells; among them, CD2 ligand CD58, has been shown
to costimulate memory NK cell responses [33]. Moreover,
monocyte-derived IL-12, probably stimulated through FcγR
engagement by anti-CD20-opsonized targets, likely mediates
a critical contribution through the upregulation of CD25, as
demonstrated by a recent report [77].
An extensive cell division, along with an induced expres-
sion of a functional high-affinity IL-2 receptor (IL-2R)
αβγ, is also observed in cytokine-induced memory-like
NK cells [39].
4. Perspectives
Based on their peculiarities, memory NK cell exploitment in
adoptive therapy strategies is considered a particularly attrac-
tive tool in anticancer therapeutic perspective and is already a
reality. Indeed, phase I clinical trials based on adoptive trans-
fer of cytokine-induced memory-like NK cells for patients
with relapsed or refractory AML [45], or in vitro expanded
NK cells with an inducible adaptive phenotype in advanced
cancer [83], are ongoing. The possibility to enhance memory
NK cell antitumor functions through genetic manipulation
has been suggested by a recent work showing that
CAR-transduced terminally differentiated/adaptive NK cells
exhibit superior effector functions when compared to other
NK subsets [84].
Future studies are needed to uncover relevant aspects of
memory NK cell biology in order to optimize their clinical
application. A better definition of the phenotypic and func-
tional heterogeneity in terms of tumor recognition capability,
the possibility to in vitro manipulate or selectively expand
memory NK cells endowed with selected receptor repertoire,
the GMP-compliant adaptation of the procedure for their
in vitro expansion will be instrumental for the better exploit-
ment of NK cell memory for the ultimate benefit of treating
cancer patients.
Importantly, the enhanced responsiveness and expansion
capability in response to mAb-coated tumors may guide
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future attempts to combine strategies based on the adoptive
transfer of in vitro expanded memory NK cells and
tumor-targeting therapeutic mAbs, whose clinical responses
are burdened by a significant proportion of relapses. Indeed,
the promotion of an endogenous long-lasting adaptive anti-
tumor immune response that may be highly relevant in
maintaining long-term protection is becoming a major goal
for improving the efficacy of mAb-based therapies.
It is worth investigating the possible contribution ofmem-
ory NK cells to the development of the so-called “vaccinal
effect” of therapeutic mAbs. Indeed, thanks to their amplified
capability to produce cytokines upon mAb-opsonized
tumor recognition, memory NK cells could participate to
the development of adaptive antitumor immune responses,
required for the long-term protection of mAb-treated
patients [8, 85, 86].
Conflicts of Interest
The authors declare no conflict of interest for this article.
Acknowledgments
CC received a grant from the Italian Ministry of University
and Research (MIUR) SIR 2014 (RBSI14022M). SB is a recip-
ient of an Italian Association for Cancer Research (AIRC)
fellowship.
References
[1] L. L. Lanier, “Up on the tightrope: natural killer cell activation
and inhibition,” Nature Immunology, vol. 9, no. 5, pp. 495–
502, 2008.
[2] E. O. Long, H. Sik Kim, D. Liu, M. E. Peterson, and
S. Rajagopalan, “Controlling natural killer cell responses: inte-
gration of signals for activation and inhibition,” Annual
Review of Immunology, vol. 31, no. 1, pp. 227–258, 2013.
[3] A. Martín-Fontecha, L. L. Thomsen, S. Brett et al., “Induced
recruitment of NK cells to lymph nodes provides IFN-γ for
TH1 priming,” Nature Immunology, vol. 5, no. 12, pp. 1260–
1265, 2004.
[4] T. Walzer, M. Dalod, S. H. Robbins, L. Zitvogel, and E. Vivier,
“Natural-killer cells and dendritic cells: “l’union fait la force”,”
Blood, vol. 106, no. 7, pp. 2252–2258, 2005.
[5] I. S. Schuster, J. D. Coudert, C. E. Andoniou, and M. A.
Degli-Esposti, ““Natural regulators”: NK cells as modulators
of T cell immunity,” Frontiers in Immunology, vol. 7, p. 235,
2016.
[6] R. P. Taylor and M. A. Lindorfer, “Immunotherapeutic
mechanisms of anti-CD20 monoclonal antibodies,” Current
Opinion in Immunology, vol. 20, no. 4, pp. 444–449, 2008.
[7] G. J. Weiner, “Building better monoclonal antibody-based
therapeutics,” Nature Reviews Cancer, vol. 15, no. 6, pp. 361–
370, 2015.
[8] S. Battella, M. C. Cox, A. Santoni, and G. Palmieri, “Natural
killer (NK) cells and anti-tumor therapeutic mAb: unexplored
interactions,” Journal of Leukocyte Biology, vol. 99, no. 1,
pp. 87–96, 2016.
[9] N. Anfossi, P. André, S. Guia et al., “Human NK cell education
by inhibitory receptors for MHC class I,” Immunity, vol. 25,
no. 2, pp. 331–342, 2006.
[10] A. Cerwenka and L. L. Lanier, “Natural killer cell memory in
infection, inflammation and cancer,” Nature Reviews Immu-
nology, vol. 16, no. 2, pp. 112–123, 2016.
[11] A. Rölle and P. Brodin, “Immune adaptation to environmental
influence: the case of NK cells and HCMV,” Trends in Immu-
nology, vol. 37, no. 3, pp. 233–243, 2016.
[12] B. Tesi, H. Schlums, F. Cichocki, and Y. T. Bryceson, “Epige-
netic regulation of adaptive NK cell diversification,” Trends
in Immunology, vol. 37, no. 7, pp. 451–461, 2016.
[13] J. G. O'Leary, M. Goodarzi, D. L. Drayton, and U. H. von
Andrian, “T cell- and B cell-independent adaptive immunity
mediated by natural killer cells,” Nature Immunology, vol. 7,
no. 5, pp. 507–516, 2006.
[14] S. Paust, H. S. Gill, B. Z. Wang et al., “Critical role for the che-
mokine receptor CXCR6 in NK cell-mediated antigen-specific
memory of haptens and viruses,” Nature Immunology, vol. 11,
no. 12, pp. 1127–1135, 2010.
[15] M. T. Orr, J. C. Sun, D. G. T. Hesslein et al., “Ly49H signaling
through DAP10 is essential for optimal natural killer cell
responses to mouse cytomegalovirus infection,” The Journal
of Experimental Medicine, vol. 206, no. 4, pp. 807–817, 2009.
[16] J. C. Sun, J. N. Beilke, and L. L. Lanier, “Adaptive immune fea-
tures of natural killer cells,” Nature, vol. 457, no. 7229,
pp. 557–561, 2009.
[17] M. Gumá, A. Angulo, C. Vilches, N. Gómez-Lozano,
N. Malats, and M. López-Botet, “Imprint of human cytomega-
lovirus infection on the NK cell receptor repertoire,” Blood,
vol. 104, no. 12, pp. 3664–3671, 2004.
[18] V. Béziat, O. Dalgard, T. Asselah et al., “CMV drives clonal
expansion of NKG2C+ NK cells expressing self-specific KIRs
in chronic hepatitis patients,” European Journal of Immunol-
ogy, vol. 42, no. 2, pp. 447–457, 2012.
[19] I. Hwang, T. Zhang, J. M. Scott et al., “Identification of human
NK cells that are deficient for signaling adaptor FcRγ and spe-
cialized for antibody-dependent immune functions,” Interna-
tional Immunology, vol. 24, no. 12, pp. 793–802, 2012.
[20] J. Lee, T. Zhang, I. Hwang et al., “Epigenetic modification and
antibody-dependent expansion of memory-like NK cells in
human cytomegalovirus-infected individuals,” Immunity,
vol. 42, no. 3, pp. 431–442, 2015.
[21] H. Schlums, F. Cichocki, B. Tesi et al., “Cytomegalovirus infec-
tion drives adaptive epigenetic diversification of NK cells with
altered signaling and effector function,” Immunity, vol. 42,
no. 3, pp. 443–456, 2015.
[22] S. Lopez-Verges, J. M. Milush, B. S. Schwartz et al., “Expansion
of a unique CD57+NKG2Chi natural killer cell subset during
acute human cytomegalovirus infection,” Proceedings of the
National Academy of Sciences, vol. 108, no. 36, pp. 14725–
14732, 2011.
[23] B. Foley, S. Cooley, M. R. Verneris et al., “Cytomegalovirus
reactivation after allogeneic transplantation promotes a lasting
increase in educated NKG2C+ natural killer cells with potent
function,” Blood, vol. 119, no. 11, pp. 2665–2674, 2012.
[24] V. Beziat, L. L. Liu, J. A. Malmberg et al., “NK cell responses to
cytomegalovirus infection lead to stable imprints in the human
KIR repertoire and involve activating KIRs,” Blood, vol. 121,
no. 14, pp. 2678–2688, 2013.
[25] M. Luetke-Eversloh, Q. Hammer, P. Durek et al., “Human
cytomegalovirus drives epigenetic imprinting of the IFNG
locus in NKG2Chi natural killer cells,” PLoS Pathogens,
vol. 10, no. 10, article e1004441, 2014.
6 Journal of Immunology Research
[26] L. L. Lanier, B. Corliss, J. Wu, and J. H. Phillips, “Association of
DAP12 with activating CD94/NKG2C NK cell receptors,”
Immunity, vol. 8, no. 6, pp. 693–701, 1998.
[27] V. M. Braud, D. S. J. Allan, C. A. O'Callaghan et al., “HLA-E
binds to natural killer cell receptors CD94/NKG2A, B and
C,” Nature, vol. 391, no. 6669, pp. 795–799, 1998.
[28] Q. Hammer and C. Romagnani, “About training and memory:
NK-cell adaptation to viral infections,” Advances in Immunol-
ogy, vol. 133, pp. 171–207, 2017.
[29] M. Della Chiesa, M. Falco, M. Podesta et al., “Phenotypic and
functional heterogeneity of human NK cells developing after
umbilical cord blood transplantation: a role for human cyto-
megalovirus?,” Blood, vol. 119, no. 2, pp. 399–410, 2012.
[30] B. Foley, S. Cooley, M. R. Verneris et al., “Human cytomegalo-
virus (CMV)-induced memory-like NKG2C+ NK cells are
transplantable and expand in vivo in response to recipient
CMV antigen,” The Journal of Immunology, vol. 189, no. 10,
pp. 5082–5088, 2012.
[31] L.Muccio,A. Bertaina,M. Falco et al., “Analysis ofmemory-like
natural killer cells in human cytomegalovirus-infected children
undergoing αβ+T and B cell-depleted hematopoietic stem
cell transplantation for hematological malignancies,” Hae-
matologica, vol. 101, no. 3, pp. 371–381, 2016.
[32] Q. Hammer, T. Rückert, E. M. Borst et al., “Peptide-specific
recognition of human cytomegalovirus strains controls adap-
tive natural killer cells,” Nature Immunology, vol. 19, no. 5,
pp. 453–463, 2018.
[33] L. L. Liu, J. Landskron, E. H. Ask et al., “Critical role of CD2
co-stimulation in adaptive natural killer cell responses
revealed in NKG2C-deficient humans,” Cell Reports, vol. 15,
no. 5, pp. 1088–1099, 2016.
[34] T. Zhang, J. M. Scott, I. Hwang, and S. Kim, “Cutting edge:
antibody-dependent memory-like NK cells distinguished by
FcRγ deficiency,” The Journal of Immunology, vol. 190, no. 4,
pp. 1402–1406, 2013.
[35] A. Muntasell, A. Pupuleku, E. Cisneros et al., “Relationship of
NKG2C copy number with the distribution of distinct
cytomegalovirus-induced adaptive NK cell subsets,” The
Journal of Immunology, vol. 196, no. 9, pp. 3818–3827, 2016.
[36] M. A. Cooper, J. M. Elliott, P. A. Keyel, L. Yang, J. A. Carrero,
and W. M. Yokoyama, “Cytokine-induced memory-like
natural killer cells,” Proceedings of the National Academy of
Sciences, vol. 106, no. 6, pp. 1915–1919, 2009.
[37] M. P. Keppel, L. Yang, and M. A. Cooper, “Murine NK cell
intrinsic cytokine-induced memory-like responses are main-
tained following homeostatic proliferation,” The Journal of
Immunology, vol. 190, no. 9, pp. 4754–4762, 2013.
[38] J. Ni, M. Miller, A. Stojanovic, N. Garbi, and A. Cerwenka,
“Sustained effector function of IL-12/15/18-preactivated NK
cells against established tumors,” The Journal of Experimental
Medicine, vol. 209, no. 13, pp. 2351–2365, 2012.
[39] R. Romee, S. E. Schneider, J. W. Leong et al., “Cytokine activa-
tion induces human memory-like NK cells,” Blood, vol. 120,
no. 24, pp. 4751–4760, 2012.
[40] C. E. Behrendt, J. Rosenthal, E. Bolotin, R. Nakamura, J. Zaia,
and S. J. Forman, “Donor and recipient CMV serostatus and
outcome of pediatric allogeneic HSCT for acute leukemia in
the era of CMV-preemptive therapy,” Biology of Blood and
Marrow Transplantation, vol. 15, no. 1, pp. 54–60, 2009.
[41] A. H. Elmaagacli, N. K. Steckel, M. Koldehoff et al., “Early
human cytomegalovirus replication after transplantation is
associated with a decreased relapse risk: evidence for a putative
virus-versus-leukemia effect in acute myeloid leukemia
patients,” Blood, vol. 118, no. 5, pp. 1402–1412, 2011.
[42] M. L. Green, W. M. Leisenring, H. Xie et al., “CMV reactiva-
tion after allogeneic HCT and relapse risk: evidence for early
protection in acute myeloid leukemia,” Blood, vol. 122, no. 7,
pp. 1316–1324, 2013.
[43] S. Ito, P. Pophali, W. CO et al., “CMV reactivation is associated
with a lower incidence of relapse after allo-SCT for CML,”
Bone Marrow Transplantation, vol. 48, no. 10, pp. 1313–
1316, 2013.
[44] F. Cichocki, S. Cooley, Z. Davis et al., “CD56dimCD57+-
NKG2C+ NK cell expansion is associated with reduced leuke-
mia relapse after reduced intensity HCT,” Leukemia, vol. 30,
no. 2, pp. 456–463, 2016.
[45] R. Romee, M. Rosario, M. M. Berrien-Elliott et al., “Cytoki-
ne-induced memory-like natural killer cells exhibit enhanced
responses against myeloid leukemia,” Science Translational
Medicine, vol. 8, no. 357, article 357ra123, 2016.
[46] J. Ni, O. Hölsken, M. Miller et al., “Adoptively transferred
natural killer cells maintain long-term antitumor activity by
epigenetic imprinting and CD4+ T cell help,” OncoImmunol-
ogy, vol. 5, no. 9, article e1219009, 2016.
[47] V. Bachanova, S. Cooley, T. E. Defor et al., “Clearance of acute
myeloid leukemia by haploidentical natural killer cells is
improved using IL-2 diphtheria toxin fusion protein,” Blood,
vol. 123, no. 25, pp. 3855–3863, 2014.
[48] Y. Zhang, D. L. Wallace, C. M. de Lara et al., “In vivo kinetics
of human natural killer cells: the effects of ageing and acute
and chronic viral infection,” Immunology, vol. 121, no. 2,
pp. 258–265, 2007.
[49] C. T. Lutz, A. Karapetyan, A. al-Attar et al., “Human NK cells
proliferate and die in vivo more rapidly than T cells in healthy
young and elderly adults,” The Journal of Immunology,
vol. 186, no. 8, pp. 4590–4598, 2011.
[50] M. A. F. Corat, H. Schlums, C. Wu et al., “Acquired somatic
mutations in PNH reveal long-term maintenance of adaptive
NK cells independent of HSPCs,” Blood, vol. 129, no. 14,
pp. 1940–1946, 2017.
[51] H. Schlums, M. Jung, H. Han et al., “Adaptive NK cells can
persist in patients with GATA2 mutation depleted of stem
and progenitor cells,” Blood, vol. 129, no. 14, pp. 1927–1939,
2017.
[52] F. Cichocki, C. Y. Wu, B. Zhang et al., “ARID5B regulates met-
abolic programming in human adaptive NK cells,” The Journal
of Experimental Medicine, vol. 215, no. 9, pp. 2379–2395, 2018.
[53] A. M. Beaulieu, C. L. Zawislak, T. Nakayama, and J. C. Sun,
“The transcription factor Zbtb32 controls the proliferative
burst of virus-specific natural killer cells responding to infec-
tion,” Nature Immunology, vol. 15, no. 6, pp. 546–553, 2014.
[54] G. Min-Oo, N. A. Bezman, S. Madera, J. C. Sun, and L. L.
Lanier, “Proapoptotic Bim regulates antigen-specific NK cell
contraction and the generation of the memory NK cell pool
after cytomegalovirus infection,” The Journal of Experimental
Medicine, vol. 211, no. 7, pp. 1289–1296, 2014.
[55] T. E. O’Sullivan, L. R. Johnson, H. H. Kang, and J. C. Sun,
“BNIP3- and BNIP3L-mediated mitophagy promotes the gen-
eration of natural killer cell memory,” Immunity, vol. 43, no. 2,
pp. 331–342, 2015.
[56] C. Capuano, M. Romanelli, C. Pighi et al., “Anti-CD20 therapy
acts via FcγRIIIA to diminish responsiveness of human
7Journal of Immunology Research
natural killer cells,” Cancer Research, vol. 75, no. 19, pp. 4097–
4108, 2015.
[57] M. Hasmim, Y. Messai, L. Ziani et al., “Critical role of tumor
microenvironment in shaping NK cell functions: implication
of hypoxic stress,” Frontiers in Immunology, vol. 6, p. 482,
2015.
[58] M. J. Smyth, M. W. L. Teng, J. Swann, K. Kyparissoudis, D. I.
Godfrey, and Y. Hayakawa, “CD4+CD25+ T regulatory cells
suppress NK cell-mediated immunotherapy of cancer,” The
Journal of Immunology, vol. 176, no. 3, pp. 1582–1587, 2006.
[59] A. Tanaka and S. Sakaguchi, “Regulatory T cells in cancer
immunotherapy,” Cell Research, vol. 27, no. 1, pp. 109–118,
2017.
[60] H. B. Jie, P. J. Schuler, S. C. Lee et al., “CTLA-4+ regulatory
T cells increased in cetuximab-treated head and neck cancer
patients suppress NK cell cytotoxicity and correlate with poor
prognosis,” Cancer Research, vol. 75, no. 11, pp. 2200–2210,
2015.
[61] M. K. Gleason, T. R. Lenvik, V. McCullar et al., “Tim-3 is an
inducible human natural killer cell receptor that enhances
interferon gamma production in response to galectin-9,”
Blood, vol. 119, no. 13, pp. 3064–3072, 2012.
[62] D. Sarhan, K. L. Hippen, A. Lemire et al., “Adaptive NK cells
resist regulatory T-cell suppression driven by IL37,” Cancer
Immunology Research, vol. 6, no. 7, pp. 766–775, 2018.
[63] L. Martinet and M. J. Smyth, “Balancing natural killer cell
activation through paired receptors,” Nature Reviews Immu-
nology, vol. 15, no. 4, pp. 243–254, 2015.
[64] C. Bottino, R. Castriconi, D. Pende et al., “Identification of
PVR (CD155) and nectin-2 (CD112) as cell surface ligands
for the human DNAM-1 (CD226) activating molecule,”
The Journal of Experimental Medicine, vol. 198, no. 4,
pp. 557–567, 2003.
[65] W. C. Dougall, S. Kurtulus, M. J. Smyth, and A. C. Anderson,
“TIGIT and CD96: new checkpoint receptor targets for cancer
immunotherapy,” Immunological Reviews, vol. 276, no. 1,
pp. 112–120, 2017.
[66] N. Stanietsky, H. Simic, J. Arapovic et al., “The interaction of
TIGIT with PVR and PVRL2 inhibits human NK cell cytotox-
icity,” Proceedings of the National Academy of Sciences,
vol. 106, no. 42, pp. 17858–17863, 2009.
[67] N. Stanietsky, T. L. Rovis, A. Glasner et al., “Mouse TIGIT
inhibits NK-cell cytotoxicity upon interaction with PVR,”
European Journal of Immunology, vol. 43, no. 8, pp. 2138–
2150, 2013.
[68] D. Sarhan, F. Cichocki, B. Zhang et al., “Adaptive NK cells
with low TIGIT expression are inherently resistant to
myeloid-derived suppressor cells,” Cancer Research, vol. 76,
no. 19, pp. 5696–5706, 2016.
[69] A. Muntasell, M. C. Ochoa, L. Cordeiro et al., “Targeting
NK-cell checkpoints for cancer immunotherapy,” Current
Opinion in Immunology, vol. 45, pp. 73–81, 2017.
[70] G. Trinchieri and N. Valiante, “Receptors for the Fc fragment
of IgG on natural killer cells,” Nature Immunology, vol. 12,
no. 4-5, pp. 218–234, 1993.
[71] C. Capuano, C. Pighi, R. Molfetta et al., “Obinutuzumab--
mediated high-affinity ligation of FcγRIIIA/CD16 primes
NK cells for IFNγ production,” OncoImmunology, vol. 6,
no. 3, article e1290037, 2017.
[72] O. Letourneur, I. C. Kennedy, A. T. Brini, J. R. Ortaldo, J. J.
O'Shea, and J. P. Kinet, “Characterization of the family of
dimers associated with Fc receptors (Fc epsilon RI and Fc
gamma RIII),” The Journal of Immunology, vol. 147, no. 8,
pp. 2652–2656, 1991.
[73] J. T. Grier, L. R. Forbes, L. Monaco-Shawver et al., “Human
immunodeficiency-causing mutation defines CD16 in sponta-
neous NK cell cytotoxicity,” Journal of Clinical Investigation,
vol. 122, no. 10, pp. 3769–3780, 2012.
[74] C. Capuano, S. Battella, C. Pighi et al., “Tumor-targeting
anti-CD20 antibodies mediate in vitro expansion of memory
natural killer cells: impact of CD16 affinity ligation conditions
and in vivo priming,” Frontiers in Immunology, vol. 9, p. 1031,
2018.
[75] S. Sivori, D. Pende, C. Bottino et al., “NKp46 is the major trig-
gering receptor involved in the natural cytotoxicity of fresh or
cultured human NK cells. Correlation between surface density
of NKp46 and natural cytotoxicity against autologous, alloge-
neic or xenogeneic target cells,” European Journal of Immunol-
ogy, vol. 29, no. 5, pp. 1656–1666, 1999.
[76] M. Gumá, M. Budt, A. Sáez et al., “Expansion of
CD94/NKG2C+ NK cells in response to human
cytomegalovirus-infected fibroblasts,” Blood, vol. 107, no. 9,
pp. 3624–3631, 2006.
[77] A. Rölle, J. Pollmann, E. M. Ewen et al., “IL-12-producing
monocytes and HLA-E control HCMV-driven NKG2C+ NK
cell expansion,” Journal of Clinical Investigation, vol. 124,
no. 12, pp. 5305–5316, 2014.
[78] L. L. Liu, V. Béziat, V. Y. S. Oei et al., “Ex vivo expanded
adaptive NK cells effectively kill primary acute lymphoblastic
leukemia cells,” Cancer Immunology Research, vol. 5, no. 8,
pp. 654–665, 2017.
[79] A. Romanski, G. Bug, S. Becker et al., “Mechanisms of
resistance to natural killer cell-mediated cytotoxicity in acute
lymphoblastic leukemia,” Experimental Hematology, vol. 33,
no. 3, pp. 344–352, 2005.
[80] J. Zhou, F. S. Amran, M. Kramski et al., “An NK cell popula-
tion lacking FcRγ is expanded in chronically infected HIV
patients,” The Journal of Immunology, vol. 194, no. 10,
pp. 4688–4697, 2015.
[81] H. S. Warren and B. F. Kinnear, “Quantitative analysis of the
effect of CD16 ligation on human NK cell proliferation,” The
Journal of Immunology, vol. 162, no. 2, pp. 735–742, 1999.
[82] H. R. Lee, C. H. Son, E. K. Koh et al., “Expansion of cytotoxic
natural killer cells using irradiated autologous peripheral blood
mononuclear cells and anti-CD16 antibody,” Scientific
Reports, vol. 7, no. 1, p. 11075, 2017.
[83] F. Cichocki, B. Valamehr, R. Bjordahl et al., “GSK3 inhibition
drives maturation of NK cells and enhances their antitumor
activity,” Cancer Research, vol. 77, no. 20, pp. 5664–5675,
2017.
[84] V. Y. S. Oei, M. Siernicka, A. Graczyk-Jarzynka et al., “Intrinsic
functional potential of NK-cell subsets constrains retargeting
driven by chimeric antigen receptors,” Cancer Immunology
Research, vol. 6, no. 4, pp. 467–480, 2018.
[85] R. Abès, E. Gélizé, W. H. Fridman, and J. L. Teillaud, “Long--
lasting antitumor protection by anti-CD20 antibody through
cellular immune response,” Blood, vol. 116, no. 6, pp. 926–
934, 2010.
[86] M. B. Pampena and E. M. Levy, “Natural killer cells as helper
cells in dendritic cell cancer vaccines,” Frontiers in Immunol-
ogy, vol. 6, p. 13, 2015.
8 Journal of Immunology Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
